The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma
Open accessAbstract
BACKGROUND: Despite the observed association between diabetes mellitus and hepatocellular carcinoma (HCC), little is known about the effect of diabetes duration before HCC diagnosis and whether some diabetes medications reduced the risk of HCC development. This objective of the current study was to determine the association between HCC risk and diabetes duration and type of diabetes treatment. METHODS: A total of 420 patients with HCC and 1104 healthy controls were enrolled in an ongoing hospital‐based case‐control study. Multivariate logistic regression models were used to adjust for HCC risk factors. RESULTS: The prevalence of diabetes mellitus was 33.3% in patients with HCC and 10.4% in the control group, yielding an adjusted odds ratio (AOR) of 4.2 (95% confidence interval [95% CI], 3.0‐5.9). In 87% of cases, diabetes was present before the diagnosis of HCC, yielding an AOR of 4.4 (95% CI, 3.0‐6.3). Compared with patients with a diabetes duration of 2 to 5 years, the estimated AORs for those with a diabetes duration of 6 to 10 years and those with a diabetes duration >10 years were 1.8 (95% CI, 0.8‐4.1) and 2.2 (95% CI, 1.2‐4.8), respectively. With respect to diabetes treatment, the AORs were 0.3 (95% CI, 0.2‐0.6), 0.3 (95% CI, 0.1‐0.7), 7.1 (95% CI, 2.9‐16.9), 1.9 (95% CI, 0.8‐4.6), and 7.8 (95% CI, 1.5‐40.0) for those treated with biguanides, thiazolidinediones, sulfonylureas, insulin, and dietary control, respectively. CONCLUSIONS: Diabetes appears to increase the risk of HCC, and such risk is correlated with a long duration of diabetes. Relying on dietary control and treatment with sulfonylureas or insulin were found to confer the highest magnitude of HCC risk, whereas treatment with biguanides or thiazolidinediones was associated with a 70% HCC risk reduction among diabetics. Cancer 2010. © 2010 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
Harris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma
El-serag, H. B., Tran, T., & Everhart, J. E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.10.065 · Cited by 1,230
Pharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
Nonalcoholic steatohepatitis: An expanded clinical entity
Bacon, B. R., Farahvash, M. J., Janney, C. G., & Neuschwander-Tetri, B. A. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90235-6 · Cited by 1,144
Oral Antidiabetic Agents: Current Role in Type 2 Diabetes Mellitus
Krentz, A. J., & Bailey, C. J. (2005) · Drugs · doi:10.2165/00003495-200565030-00005 · Cited by 1,108
Selection of Controls in Case-Control Studies
Wacholder, S., McLaughlin, J. K., Silverman, D. T., & Mandel, J. S. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116396 · Cited by 998
Thomas, N., K, S., & Kapoor, N. (2016) · A Practical Guide to Diabetes Mellitus · doi:10.5005/jp/books/12651_7 · Cited by 943
Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
El–Serag, H. B., Hampel, H., & Javadi, F. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2005.12.007 · Cited by 826
Diabetes Mellitus as a Predictor of Cancer Mortality in a Large Cohort of US Adults
Coughlin, S. S., Calle, E. E., Teras, L. R., Petrelli, J., & Thun, M. J. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh161 · Cited by 795
Hassan, M. M., Hwang, L.-Y., Hatten, C. J., Swaim, M., Li, D., Abbruzzese, J. L., Beasley, P., & Patt, Y. Z. (2002) · Hepatology · doi:10.1053/jhep.2002.36780 · Cited by 762
Self-citationDavila, J. A., Morgan, R. O., Shaib, Y., McGlynn, K. A., & El-Serag, H. B. (2005) · Gut · doi:10.1136/gut.2004.052167 · Cited by 704
Metformin in non-alcoholic steatohepatitis.
Marchesini, G., Bianchi, G., Tomassetti, S., Zoli, M., & Melchionda, N. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06042-1 · Cited by 682
Metformin reverses fatty liver disease in obese, leptin-deficient mice.
Lin, H. Z., Yang, S. Q., Chuckaree, C., Kuhajda, F., Ronnet, G., & Diehl, A. M. (2000) · Nature Medicine · doi:10.1038/79697 · Cited by 673
Wideroff, L., Gridley, G., Chow, W. H., Linet, M., Mellemkjaer, L., Olsen, J. H., Keehn, S., & Borch-Johnsen, K. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.18.1360 · Cited by 627
Selection of Controls in Case-Control Studies: II. Types of Controls
Wacholder, S., Silverman, D. T., McLaughlin, J. K., & Mandel, J. S. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116397 · Cited by 625
Chen, C., Yang, H., Yang, W., Liu, C., Chen, P., You, S., Wang, L., Sun, C., Lu, S., Chen, D., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.073 · Cited by 549
Economic Costs of Diabetes in the U.S. in 2002Preprint
Dall, T. M., Nikolov, P., & Hogan, P. F. (2003) · RePEc: Research Papers in Economics · Cited by 482
Self-report and medical record report agreement of selected medical conditions in the elderly.
Bush, T. L., Miller, S. R., Golden, A. L., & Hale, W. E. (1989) · American Journal of Public Health · doi:10.2105/ajph.79.11.1554 · Cited by 465
Selection of Controls in Case-Control Studies: III. Design Options
Wacholder, S., Silverman, D. T., McLaughlin, J. K., & Mandel, J. S. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116398 · Cited by 443
Metformin in the treatment of patients with non‐alcoholic steatohepatitis
Uygun, A., Kadayifci, A., Isik, A. T., Ozgurtas, T., Deveci, S., Tuzun, A., Yesilova, Z., Gulsen, M., & Dagalp, K. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.01888.x · Cited by 405
Excess Risk of Primary Liver Cancer in Patients With Diabetes Mellitus
Adami, H.-O., Chow, W.-H., Nyren, O., Berne, C., Linet, M. S., Ekbom, A., Wolk, A., McLaughlin, J. K., & Fraumeni, J. F. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.20.1472 · Cited by 373
Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial
Nair, S., Diehl, A. M., Wiseman, M., Farr, G. H., & Perrillo, R. P. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02025.x · Cited by 369
Simpson, C. F., Boyd, C. M., Carlson, M. C., Griswold, M. E., Guralnik, J. M., & Fried, L. P. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52021.x · Cited by 334
Veldt, B. J., Chen, W., Heathcote, J. E., Wedemeyer, H., Reichen, J., Hofmann, P. W., de Knegt, R. J., Zeuzem, S., Manns, M. P., Hansen, B. E., et al. (2008) · Hepatology · doi:10.1002/hep.22251 · Cited by 284
Yuan, J., Govindarajan, S., Arakawa, K., & Yu, M. C. (2004) · Cancer · doi:10.1002/cncr.20427 · Cited by 275
Liver Disease in Patients With Diabetes Mellitus
Harrison, S. A. (2006) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000190774.91875.d2 · Cited by 197
Alexia, C., Fallot, G., Lasfer, M., Schweizer-Groyer, G., & Groyer, A. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.05.029 · Cited by 191
Yu, M. C., Henderson, B. E., Tong, M. J., & Govindarajan, S. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1820 · Cited by 190
Lai, M., Hsieh, M., Chiu, Y., & Chen, T. H. (2006) · Hepatology · doi:10.1002/hep.21208 · Cited by 188
Diabetes increases the risk of acute hepatic failure
El–Serag, H. B., & Everhart, J. E. (2002) · Gastroenterology · doi:10.1053/gast.2002.33650 · Cited by 174
Hassan, M. M., Kaseb, A., Li, D., Patt, Y. Z., Vauthey, J.-N., Thomas, M. B., Curley, S. A., Spitz, M. R., Sherman, S. I., Abdalla, E. K., et al. (2009) · Hepatology · doi:10.1002/hep.22793 · Cited by 173
Self-citationOhki, T., Tateishi, R., Sato, T., Masuzaki, R., Imamura, J., Goto, T., Yamashiki, N., Yoshida, H., Kanai, F., Kato, N., et al. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.02.012 · Cited by 160
Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease
Donadon, V., Balbi, M., Ghersetti, M., Grazioli, S., Perciaccante, A., Valentina, G. D., Gardenal, R., Mas, M. D., Casarin, P., Zanette, G., et al. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.2506 · Cited by 144
Is it Time to Test Metformin in Breast Cancer Clinical Trials?
Cazzaniga, M., Bonanni, B., Guerrieri‐Gonzaga, A., & DeCensi, A. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0871 · Cited by 134
Narrative Review: Hepatobiliary Disease in Type 2 Diabetes Mellitus
Tolman, K. G., Fonseca, V. A., Tan, M. H., & Dalpiaz, A. S. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-12-200412210-00011 · Cited by 130
Hyperglycemia decreases mitochondrial function: The regulatory role of mitochondrial biogenesis
Palmeira, C. M., Rolo, A. P., Berthiaume, J. M., Bjork, J. A., & Wallace, K. B. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2007.07.015 · Cited by 126
Tanaka, S., & Wands, J. R. (1996) · PubMed · Cited by 122
Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes
Tanaka, S., Mohr, L., Schmidt, E. V., Sugimachi, K., & Wands, J. R. (1997) · Hepatology · doi:10.1002/hep.510260310 · Cited by 108
Prognosis of hepatocellular carcinoma with diabetes mellitus after hepatic resection
Ikeda, Y., Shimada, M., Hasegawa, H., Gion, T., Kajiyama, K., Shirabe, K., Yanaga, K. K., Takenaka, K., & Sugimachi, K. (1998) · Hepatology · doi:10.1002/hep.510270615 · Cited by 97
Hassan, M. M., Spitz, M. R., Thomas, M. B., Curley, S. A., Patt, Y. Z., Vauthey, J., Glover, K. Y., Kaseb, A. O., Lozano, R. D., El‐Deeb, A. S., et al. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.08.016 · Cited by 95
Self-citationHassan, M. M., Spitz, M. R., Thomas, M. B., El‐Deeb, A. S., Glover, K. Y., Nguyen, N. T., Chan, W., Kaseb, A. O., Curley, S. A., Vauthey, J., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23730 · Cited by 91
Self-citationThe effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes
Donnelly, L. A., Doney, A. S. F., Hattersley, A. T., Morris, A. D., & Pearson, E. R. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01755.x · Cited by 88
Implications of the hyperinsulinaemia-diabetes-cancer link for preventive efforts.
Moore, M. A., Park, C. B., & Tsuda, H. (1998) · PubMed · Cited by 86
Komura, T., Mizukoshi, E., Kita, Y., Sakurai, M., Takata, Y., Arai, K., Yamashita, T., Ohta, T., Shimizu, K., Nakamoto, Y., et al. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01354.x · Cited by 85
Too much of a good thing: why it is bad to stimulate the beta cell to secrete insulin
Aston‐Mourney, K., Proietto, J., Morahan, G., & Andrikopoulos, S. (2008) · Diabetologia · doi:10.1007/s00125-008-0930-2 · Cited by 79
Long-Term Efficacy of Metformin Therapy in Nonobese Individuals With Type 2 Diabetes
Ong, C. R., Molyneaux, L. M., Constantino, M., Twigg, S. M., & Yue, D. K. (2006) · Diabetes Care · doi:10.2337/dc06-0827 · Cited by 77
Review article: steatosis, the metabolic syndrome and cancer
Bugianesi, E. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02594.x · Cited by 71
The management of diabetes in patients with advanced cancer
Poulson, J. (1997) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(96)00326-0 · Cited by 65
Oliveras-Ferraros, C., Vazquez-Martin, A., & Menendez, J. A. (2009) · Cell Cycle · doi:10.4161/cc.8.10.8406 · Cited by 52 · cited 1×
“Although the mechanism for the antineoplastic activity of metformin is not fully understood, there is substantial evidence suggesting that metformin suppresses cellular proliferation and protein synthesis with AMP-independent protein kinase activation in both malignant and nonmalignant cells.(52,53) A recent review by…”
BackgroundThe Multifaceted Associations of Hepatobiliary Disease and Diabetes
Bell, D. S. H., & Allbright, E. (2007) · Endocrine Practice · doi:10.4158/ep.13.3.300 · Cited by 52
Accuracy of Patients' Reports of Comorbid Disease and Their Association With Mortality in ESRD
Cavanaugh, K. L., Merkin, S. S., Plantinga, L., Fink, N. E., Sadler, J. H., & Powe, N. R. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.02.001 · Cited by 45
Torisu, Y., Ikeda, K., Kobayashi, M., Hosaka, T., Sezaki, H., Akuta, N., Kawamura, Y., Yatsuji, H., Suzuki, F., Suzuki, Y., et al. (2007) · Hepatology Research · doi:10.1111/j.1872-034x.2007.00077.x · Cited by 37
Spitz, M. R., Fueger, J. J., Borrud, L. G., & Newell, G. R. (1988) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(18)31172-3 · Cited by 35
Spitz, M. R., Fueger, J. J., & Newell, G. R. (1988) · PubMed · Cited by 25
Cited by
Epidemiology and Management of Hepatocellular Carcinoma
Kulik, L., & El-Serag, H. B. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.08.065 · Cited by 1,735
Vigneri, P., Frasca, F., Sciacca, L., Pandini, G., & Vigneri, R. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0087 · Cited by 1,009
Michelotti, G. A., Machado, M. V., & Diehl, A. M. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.183 · Cited by 974
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0157 · Cited by 918
Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace
Baffy, G., Brunt, E. M., & Caldwell, S. H. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.10.027 · Cited by 858
Metadata
- Authors
- Hassan, M. M., Curley, S. A., Li, D., Kaseb, A., Davila, M., Abdalla, E. K., Javle, M., Moghazy, D. M., Lozano, R. D., Abbruzzese, J. L., & Vauthey, J.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2010-04-06
- Volume
- 116
- Issue
- 8
- Pages
- 1938-1946
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2059201072
- Cited by
- 309
- References
- 59
- FWCI
- 10.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.